GoodRx Expands Access to Eli Lilly and Company’s New Oral GLP-1, Foundayo™, and Zepbound® KwikPen® with Self-Pay Pricing at More Than 70,000 Pharmacies Nationwide
Thursday, April 9, 2026 1 min read
Key Takeaway: GoodRx has partnered with Eli Lilly to enhance access to the newly FDA-approved oral GLP-1 medication, Foundayo. Self-pay patients can obtain Foundayo through GoodRx at a starting price of $149 per month. This initiative aims to provide transparent pricing and improve medication accessibility across more than 70,000 pharmacies nationwide.
Price reaction · baseline $953.3 (2026-04-08 close) · hit after-hours · 4 other LLY headline(s) in the window, move may be shared
day 0 close
+0.2%
Market Sentiment Analysis
POSITIVE FACTORS
GoodRx expands access to a new medication.
Foundayo offers transparent pricing for patients.
Eligible patients can access the medication at a competitive price.
Full Press Release Details
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced that it is working with Eli Lilly and Company to expand access to the newly FDA-approved oral GLP-1 medication, Foundayo™ (orforglipron). Eligible self-pay patients can access Foundayo through GoodRx at a starting price of $149 per month, in line with the lowest available discounted cash price at launch. The offering provides transparent pricing and nationwide
Frequently Asked Questions
What is Foundayo?
Foundayo is a newly FDA-approved oral GLP-1 medication developed by Eli Lilly.
How can patients access Foundayo?
Patients can access Foundayo through GoodRx at a starting price of $149 per month.
Where is Foundayo available?
Foundayo is available at more than 70,000 pharmacies nationwide.
What is the purpose of GoodRx's partnership with Eli Lilly?
The partnership aims to expand access to Foundayo and provide transparent pricing for patients.